 SAN FRANCISCO, May 11, 2021 PRNewswire -- Kindred Biosciences, Inc. NASDAQ: KIN, a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first quarter 2021, KindredBio reported net revenues of 2.4 million and a net loss of 9.7 million, or 0.24 per share. 